已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov

医学 内科学 危险系数 肿瘤科 临床试验 无进展生存期 贝伐单抗 免疫疗法 荟萃分析 置信区间 癌症 总体生存率 化疗
作者
Aidan Lyanzhiang Tan,Raphaël Porcher,Perrine Créquit,Philippe Ravaud,Agnès Dechartres
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (15): 1686-1694 被引量:55
标识
DOI:10.1200/jco.2016.71.2109
摘要

Purpose We aimed to compare treatment effect sizes between overall survival (OS) and progression-free survival (PFS) in trials of US Food and Drug Administration–approved oncology immunotherapy drugs with results posted at ClinicalTrials.gov . Methods We searched ClinicalTrials.gov for phase II to IV cancer trials of Food and Drug Administration–approved immunotherapy drugs and selected those reporting results for both OS and PFS. For each trial, we extracted the hazard ratios (HRs) with 95% CIs for both outcomes and evaluated the differences by a ratio of HRs (rHRs): the HR for PFS to that for OS. We performed a random effects meta-analysis across trials to obtain a summary rHR. We also evaluated surrogacy of PFS for OS by the coefficient of determination and the surrogacy threshold effect, the minimal value of HR for PFS to predict a non-null effect on OS. Results We identified 51 trials assessing 14 drugs across 15 conditions. Treatment effect sizes were 17% greater, on average, with PFS than with OS (rHR, 0.83; 95% CI, 0.79 to 0.88; I 2 = 34.4%; P = .01; τ 2 = 0.0129). Nearly one half of the trials (n = 23, 45%) showed statistically significant benefits for PFS but not for OS. Differences were great for trials of obinutuzumab (rHR, 0.21; 95% CI, 0.08 to 0.54), bevacizumab (rHR, 0.75; 95% CI, 0.67 to 0.84), and rituximab (rHR, 0.79; 95% CI, 0.64 to 0.98). The coefficient of determination was 38% and the surrogacy threshold effect was 0.50. Conclusion Treatment effect sizes in trials of immunotherapy drugs were greater for PFS than for OS, with important differences for some drugs, which is consistent with surrogacy metrics. Caution must be taken when interpreting PFS in the absence of OS data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大笨鹅之家完成签到 ,获得积分10
刚刚
junyang发布了新的文献求助10
1秒前
fengfenghao完成签到,获得积分10
4秒前
6秒前
SciGPT应助科研顺利啦采纳,获得10
11秒前
牙线棒棒哒完成签到 ,获得积分10
12秒前
liwu完成签到 ,获得积分10
12秒前
13秒前
Linson完成签到,获得积分0
14秒前
失眠呆呆鱼完成签到 ,获得积分10
14秒前
明朗完成签到 ,获得积分10
15秒前
czh应助dinner采纳,获得10
15秒前
学术djw完成签到,获得积分10
16秒前
三水发布了新的文献求助10
16秒前
彭于晏应助科研通管家采纳,获得10
17秒前
17秒前
科研通AI2S应助科研通管家采纳,获得10
17秒前
17秒前
斯文败类应助科研通管家采纳,获得10
17秒前
量子星尘发布了新的文献求助10
19秒前
旺仔发布了新的文献求助10
21秒前
24秒前
28秒前
洁净雨柏发布了新的文献求助30
29秒前
ypyue完成签到,获得积分10
32秒前
知足的憨人*-*完成签到,获得积分10
32秒前
33秒前
susu发布了新的文献求助10
33秒前
alan完成签到 ,获得积分10
34秒前
朴实的热狗完成签到,获得积分10
34秒前
36秒前
38秒前
nature发布了新的文献求助10
39秒前
知足的憨人丫丫完成签到,获得积分10
39秒前
夏夏完成签到 ,获得积分10
40秒前
洁净雨柏完成签到,获得积分10
41秒前
朴素的紫安完成签到 ,获得积分10
41秒前
舒适静丹完成签到,获得积分10
41秒前
SASI完成签到 ,获得积分10
43秒前
舒适静丹发布了新的文献求助10
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520674
关于积分的说明 11204470
捐赠科研通 3257316
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877861
科研通“疑难数据库(出版商)”最低求助积分说明 806595